MTOR and acute lymphoblastic leukemia: For example, the novel dual PI3K/mTOR inhibitor NVP-BEZ235, an orally bioavailable imidazoquinoline derivative, proved to have anti-proliferative effects in several T-ALL cell lines where pro-apoptotic effects were demonstrated (82).